Search Results for: covid-19
Articles
New Lipid Facility at Evonik’s Site in Hanau to Produce Clinical & Launch Quantities of Lipids for Innovative Medicines August 2, 2022
Evonik is building a new cGMP facility to manufacture lipids for clinical development and launch of innovative medicines. The new cGMP lipid launch facility is located in….
SCHOTT Establishes Stand-Alone Company for its Pharma Business to Promote Further Growth August 1, 2022
SCHOTT has legally established a stand-alone company for its pharma business to advance its growth strategy. As a pioneer in pharma drug containment and system solutions, the international technology….
CymaBay Completes Enrollment for the RESPONSE Global Phase 3 Study Evaluating Seladelpar for Patients With Primary Biliary Cholangitis August 1, 2022
CymaBay Therapeutics, Inc. recently announced the completion of enrollment for RESPONSE, a global Phase 3 study evaluating seladelpar for patients with Primary Biliary….
Vaxxinity Presents Preclinical Data on Tau Vaccine Candidates August 1, 2022
Vaxxinity, Inc. recently presented new preclinical data on vaccine candidates targeting aberrant forms of the Tau protein for Alzheimer’s disease (AD) during a poster session at the….
Agarose Bead Technologies Triples its Production Capacity With Major Manufacturing Expansion July 11, 2022
Agarose Bead Technologies (ABT) plans a major expansion of its manufacturing capabilities, tripling its production capacity to meet the global...2022 Respiratory Drug Development eBook - Demand Accelerates Devices July 8, 2022
This fourth annual Drug Development & Delivery Respiratory eBook highlights the pMDI development path, as well as the importance of a holistic approach to that development that includes the patient and all stakeholders across the product’s life cycle.
Acer Therapeutics & Relief Therapeutics Announce China National Intellectual Property Administration Issued Utility Model Patent July 8, 2022
Acer Therapeutics Inc. and its collaboration partner, Relief Therapeutics recently announced the China National Intellectual Property Administration (CNIPA) issued Electronic...Alvotech Initiates Patient Study for Proposed Biosimilar for Eylea July 7, 2022
Alvotech recently announced the initiation of the company’s confirmatory clinical study for AVT06 (aflibercept), a biosimilar candidate to Eylea…..
Codiak BioSciences & CEPI Partner to Develop Broadly Protective Betacoronavirus Vaccine July 5, 2022
CEPI, the Coalition for Epidemic Preparedness Innovations, and Codiak BioSciences recently announced the latest funding award under CEPI’s US $200 million program to advance the development of vaccines that provide broad protection against….
DFE Pharma Expands its Inhalation Portfolio With New Launch July 5, 2022
DFE Pharma recently announced the expansion of its Dry Powder Inhalation (DPI) portfolio with the launch of Lactohale 400. The addition of Lactohale 400 further enhances the completeness of DFE Pharma’s portfolio of inhalation-grade lactose…..
US Government to Support Expansion of Croda Lipid Systems Capability June 29, 2022
Croda International Plc recently announced it has entered into a cooperative agreement with the US government in which the government will provide up to $75 million to expand the….
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis June 28, 2022
Soligenix, Inc. recently announced the US FDA has cleared the Investigational New Drug (IND) application for a Phase 2a clinical...Acer Therapeutics & Relief Therapeutics Announce Update on US FDA Review of NDA June 21, 2022
Acer Therapeutics Inc. and its collaboration partner, Relief Therapeutics recently announced the US FDA has issued a Complete Response Letter...Valneva & Pfizer Enter Equity Subscription Agreement & Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate June 20, 2022
Valneva SE and Pfizer Inc. recently announced they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15…..
VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis June 17, 2022
VYNE Therapeutics Inc. recently announced the completion of enrollment in the Phase 2a study of FMX114 for the treatment of...Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD With AIM Biologicals Program June 14, 2022
Aeterna Zentaris Inc. recently announced its Autoimmunity Modifying (AIM) Biologicals program has achieved preclinical proof-of-concept for the potential treatment of...ProteoGenix, Aseem Healthcare & Trident Biopharm Solutions Announce New Antibody Cocktail Effective Against Major Variants of SARS-CoV-2 June 7, 2022
ProteoGenix, Aseem Healthcare, and Trident Biopharm Solutions recently announced the development of a new antibody cocktail effective against major variants...SPECIAL ROUNDTABLE - Which Trends Will Have the Most Impact on Drug Development in 2022? June 6, 2022
Drug Development & Delivery posed this question to life science leaders during a recent roundtable discussion. While their responses are varied, a common theme is that COVID-19 has left a lasting impact on the industry….
Jubilant HollisterStier Enters Cooperative Agreement With US Government to Expand Critical Vaccine Manufacturing Capacity June 3, 2022
Jubilant Pharmova Limited recently announced that Jubilant Pharma Limited, a wholly owned subsidiary of the company, through one of its wholly owned subsidiaries, Jubilant HollisterStier LLC, (JHS) a leading US-based….
Evonik Invests $220 Million to Build New Lipid Production Facility for mRNA-based Therapies in the US June 2, 2022
Evonik is building a new, highly flexible, global-scale production facility for pharmaceutical lipids in the US. The new plant at...
